HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.

Abstract
We previously reported our data on telaprevir (TVR) used in combination with pegylated-interferon and ribavirin (PEG-IFN/RBV) for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). TVR substantially increases the blood levels of immunosuppressive agents such as cyclosporine and tacrolimus for drug-drug interactions. On the other hand, the effect of simeprevir (SMV) on the blood levels of these immunosuppressive agents is unclear. We report 2 patients who achieved viral responses with little effect on the blood levels of cyclosporine and tacrolimus using SMV plus PEG-IFN/RBV treatment. The first was a 71-year-old woman with HCV-related liver cirrhosis and hepatocellular carcinoma who failed to respond to PEG-IFN/RBV after living donor LT. She was treated with 40 mg/d of cyclosporine, and received SMV plus PEG-IFN/RBV treatment. The second was a 65-year-old man with HCV-related liver cirrhosis who failed to respond to PEG-IFN/RBV after living donor LT. He was treated with 3 mg/d of tacrolimus, and received SMV plus PEG-IFN/RBV treatment. Serum HCV RNA became undetectable using TaqMan polymerase chain reaction (PCR) test after 4 weeks of treatment in both patients, and no remarkable fluctuation in blood concentration was observed either in cyclosporine or tacrolimus during the 12 weeks of SMV treatment. Completion of 12-week SMV triple therapy was followed by PEG-IFNα2b plus RBV, and both patients achieved sustained virological response 12 weeks after the end of treatment. SMV plus PEG-IFNRBV treatment showed a remarkable viral response with little effect on blood levels of immunosuppressive agents for recurrent HCV genotype 1 infection after LT.
AuthorsT Kawaoka, M Imamura, H Kan, H Fujino, T Fukuhara, T Kobayashi, Y Honda, N Naeshiro, A Hiramatsu, M Tsuge, C N Hayes, Y Kawakami, H Aikata, H Ochi, K Ishiyama, H Tashiro, H Ohdan, K Chayama
JournalTransplantation proceedings (Transplant Proc) Vol. 47 Issue 3 Pg. 809-14 (Apr 2015) ISSN: 1873-2623 [Electronic] United States
PMID25891736 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Antiviral Agents
  • Immunosuppressive Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Protease Inhibitors
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Cyclosporine
  • Simeprevir
  • peginterferon alfa-2b
  • Tacrolimus
Topics
  • Aged
  • Antiviral Agents (therapeutic use)
  • Cyclosporine (blood)
  • Drug Therapy, Combination
  • Female
  • Hepatitis C (drug therapy)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Liver Cirrhosis (virology)
  • Liver Transplantation
  • Living Donors
  • Male
  • Polyethylene Glycols (therapeutic use)
  • Protease Inhibitors (therapeutic use)
  • Recombinant Proteins (therapeutic use)
  • Ribavirin (therapeutic use)
  • Simeprevir (therapeutic use)
  • Tacrolimus (blood)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: